Duality Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics. Its primary focus is on creating innovative treatments for cancer and autoimmune diseases, leveraging proprietary technology platforms to engineer targeted, potent therapies. The company's pipeline features multiple clinical-stage ADC candidates addressing a broad spectrum of difficult-to-treat malignancies, including HER2-positive cancers such as breast and endometrial cancer, as well as B7-H3 targeted therapies for small-cell lung cancer and other solid tumors. Duality Biotherapeutics distinguishes itself through strategic collaborations with major biopharmaceutical firms, enhancing its research reach and accelerating global clinical trials across numerous countries. Employing an experienced scientific team, the company has established several cutting-edge ADC technology platforms validated by partnerships and ongoing trials. While headquartered in Shanghai and incorporated in the Cayman Islands, Duality Biotherapeutics plays an increasingly significant role in the healthcare sector by advancing therapies that may complement or provide alternatives to traditional chemotherapy, aiming to address unmet needs in oncology and immunology.